25 results for “GFAP”. Showing 25 of 39,449.
GFAP isoforms in adult mouse brain with a focus on neurogenic astrocytes and reactive astrogliosis in mouse models of Alzheimer disease.
Gfap-α, Gfap-β, Gfap-γ, Gfap-δ, Gfap-κ, and a newly
Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum.
GFAP. To evaluate plasma GFAP levels throughout the entire AD continuum
Serum GFAP levels correlate with astrocyte reactivity, post-mortem brain atrophy and neurofibrillary tangles.
GFAP), a proxy of astrocyte reactivity, has been proposed as biomarker
Peripheral GFAP and NfL as early biomarkers for dementia: longitudinal insights from the UK Biobank.
GFAP and NfL levels. These results suggest that peripheral GFAP
Moderating effects of plasma glial fibrillary acidic protein along the Alzheimer's disease continuum.
GFAP concentrations. In 1FLADRC, GFAP moderated T1-Nplasma/MRI. In UCSF
Plasma GFAP outperforms CSF GFAP in detecting amyloid pathology and is associated with increased risk of clinical progression in early Alzheimer's disease.
GFAP showed a stronger association with amyloid status than CSF GFAP
Miro1 Mediates the Neuroprotective Effects of Electroacupuncture Against Cerebral Ischemia-Reperfusion Injury in Mice.
GFAP-shMiro1, AAV-GFAP-hiMiro1, and AAV-GFAP-control groups
Pathologic and clinical correlates of region-specific brain GFAP in Alzheimer's disease.
GFAP interactions with AD neuropathology on downstream outcomes. Cortical GFAP
Neurochemical regulation of the expression and function of glial fibrillary acidic protein in astrocytes.
GFAP), a type III intermediate filament, is a marker of mature
Hippocampal GFAP-positive astrocyte responses to amyloid and tau pathologies.
GFAP) released/leaked into the cerebrospinal fluid and blood is widely
Plasma GFAP for populational enrichment of clinical trials in preclinical Alzheimer's disease.
GFAP) have an increased risk of Alzheimer's disease (AD)-related
Astrocyte-Derived Estrogen Regulates Reactive Astrogliosis and is Neuroprotective following Ischemic Brain Injury.
GFAP) promoter-driven aromatase knock-out (GFAP-ARO-KO) mouse
Loss of glial fibrillary acidic protein results in decreased glutamate transport and inhibition of PKA-induced EAAT2 cell surface trafficking.
GFAP null animals demonstrated that loss of GFAP results in decreases
From scaffold to effector: reframing GFAP in neurodegeneration.
GFAP) has shifted from a passive astrocytic marker to an active
The Evaluation of Clinical Applications for the Detection of the Alzheimer's Disease Biomarker GFAP.
GFAP) is released from tissue into the bloodstream due to astrocyte
Plasma glial fibrillary acidic protein in the visual and language variants of Alzheimer's disease.
GFAP and imaging quantities. GFAP did not correlate with Aβ- or tau-PET cross
Prediction of clinical progression in nervous system diseases: plasma glial fibrillary acidic protein (GFAP).
GFAP), an intracellular type III intermediate filament protein, provides structural
Comparison of the analytical and clinical performance of three immunoassay platforms for plasma glial fibrillary acidic protein in Alzheimer's disease.
GFAP) across three immunoassay platforms. METHODS: Plasma GFAP was measured
Serum NfL, GFAP, and p-tau217 in adults with drug-resistant epilepsy and intellectual disabilities: Signs of ongoing neural injury.
GFAP), and phosphorylated tau-217 (p-tau217) in these adults
Trajectories of CSF and plasma biomarkers across Alzheimer's disease continuum: disease staging by NF-L, p-tau181, and GFAP.
GFAP. Among plasma biomarkers, we found Aβ42/Aβ40, GFAP, and p-tau231
Interactions of GFAP with ceftriaxone and phenytoin: SRCD and molecular docking and dynamic simulation.
GFAP is the major intermediate filament protein in mature astrocytes
Longitudinal blood biomarker trajectories in preclinical Alzheimer's disease.
GFAP) in a cohort of older adults at risk of AD (n = 373 total
Role of astrocyte biomarker GFAP in early diagnosis and prognosis assessment of dementia: A comprehensive review.
GFAP. We then summarize the role of GFAP in early
Blood biomarkers for predicting disability worsening in progressive multiple sclerosis: a multinational, individual participant-level analysis.
GFAP) and neurofilament light chain (NfL) may help predict confirmed
Prognostic Value of Plasma NfL and GFAP for Conversion to Alzheimer's Disease and Dementia in MCI: A Systematic Review and Robust Bayesian Meta-Analysis.
GFAP) are leading candidates, but their utility remains debated. OBJECTIVE